Gabrielsen Comments on Trump Administration’s Imposition of New Limits on ‘Guidance Documents’
February 10, 2018
The New York Times
Associate Lindsey Gabrielsen is quoted in a New York Times article, “Administration Imposes Sweeping Limits on Federal Actions Against Companies,” about the ramifications of the Justice Department’s adoption of new limits on the use of ‘guidance documents” by federal agencies.
In view of the new policy, Gabrielsen said, the government “will face serious hurdles” in enforcement actions based on violations of health care guidance documents.
Gabrielsen’s comments to the New York Times were also republished in Esquire, FierceHealthcare and MSN.
In view of the new policy, Gabrielsen said, the government “will face serious hurdles” in enforcement actions based on violations of health care guidance documents.
Gabrielsen’s comments to the New York Times were also republished in Esquire, FierceHealthcare and MSN.
Related News
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."
July 18, 2025
In the News
Aaron Maguregui Highlights Potential Compliance Concerns in Pre-Tax Wellness Claims
Foley & Lardner LLP partner Aaron Maguregui commented in The New York Times article, "Hot Dogs for Insomnia? A Kennedy Aide's Start-Up Can Get You a Tax Break," sharing insight on the growing use of medical necessity letters to support tax-advantaged purchases of wellness products.